New hope for rare adrenal cancer: can a maintenance drug keep tumors at bay?

NCT ID NCT07085572

Recruiting now Disease control Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia Source: ClinicalTrials.gov ↗

Summary

This study is testing if a drug called cemiplimab can help keep advanced adrenal cancer from getting worse in patients whose disease has responded to initial chemotherapy. The drug is an immunotherapy designed to help the body's immune system fight the cancer. Researchers want to see if giving it as a long-term 'maintenance' treatment can delay cancer progression and improve survival for people with this rare and aggressive cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENAL CORTICAL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

S.C. Oncologia - ASST Spedali Civili di Brescia
RECRUITING

Brescia, Brescia, 25123, Italy

Conditions

Explore the condition pages connected to this study.

ADRENAL CORTICAL CARCINOMA